Document:

EX-10.105

 Exhibit 10.105 

AMENDMENT TO 
 EMISPHERE
TECHNOLOGIES, INC. 
 AMENDED AND RESTATED 

13% SENIOR SECURED CONVERTIBLE NOTE 

This Amendment (“Amendment”), dated as of March 28, 2014, is entered into by and among Emisphere Technologies, Inc., a
Delaware corporation (the “Company”), and the undersigned note holders (each a “Note Holder” and collectively, the “Note Holders”). Capitalized terms used herein and not defined shall have the
meaning set forth in the Notes, as defined below. 
 WHEREAS, the Company issued an Amended and Restated 13% Senior Secured
Convertible Note to each Note Holder on May 7, 2013 (each a “Note” and collectively with the notes issued in payment of interest thereon, the “Notes”); 

WHEREAS, pursuant to Section 8(a)(xiii) of the Notes, an Event of Default shall occur on the failure of the Company to achieve the
Milestones set forth in Exhibit A hereto; 
 WHEREAS, due to unforeseen circumstances, it is not commercially practicable for
the Company to achieve certain of the Milestones (each, a “Waiver Milestone”) by the dates agreed to in the Notes; 

WHEREAS, the Company and the Note Holders desire to avoid the occurrence of an Event of Default resulting from the Company’s
failure to achieve a Waiver Milestone, and to adjust accordingly the terms and timing of the Waiver Milestones as set forth in Exhibit B attached hereto. 

NOW THEREFORE, in consideration of the premises and of the mutual covenants, conditions and agreements set forth herein and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby enter into this Amendment and agree as follows: 

 

	 	1.	Revised Milestones. Each of the undersigned Note Holders agree to replace the Waiver Milestones with the revised Milestones attached hereto as Exhibit B. Except as set forth in Exhibit B, each of the Milestones
shall remain in effect as set forth in Exhibit A. 

  

	 	2.	Representations. The Company hereby represents and warrants to the Note Holders that after giving effect to the provisions of this Amendment, no Default or Event of Default shall have occurred and be continuing.

  

	 	3.	Course of Dealings. No course of dealing on the part of the Note Holders, nor any failure or delay in the exercise of any right by the Note Holders, shall operate as a waiver thereof, and any single or partial
exercise of any such right shall not preclude any later exercise of any such right. The Note Holders’ failure at any time to require strict performance by the Company of any provision shall not affect any right of the Note Holders thereafter to
demand strict compliance and performance. Any suspension or waiver of a right must be in a signed writing. 

  

	 	4.	Legal Effect. Except as amended by this Agreement, the Notes remain in full force and effect. 

  

	 	5.	Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflict of laws provisions thereof. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the day and year first
above written. 
 This Amendment may be executed in any number of counterparts, each of which shall constitute an original, but which, when
taken together, shall constitute one instrument. One or more counterparts of this Amendment may be delivered via facsimile or other electronic means, with the intention that they shall have the same effect as an original counterpart hereof. 

 

					
	THE COMPANY:	 	EMISPHERE TECHNOLOGIES, INC.
			
		 	By:	 	 /s/ Michael R. Garone

		 	Name:	 	Michael R. Garone
		 	Title:	 	Chief Financial Officer and Corporate Secretary
		
	NOTE HOLDERS:	 	 MHR CAPITAL PARTNERS MASTER ACCOUNT LP

By MHR Advisors LLC, its general partner

			
		 		 	 /s/ Janet Yeung

		 	Name:	 	Janet Yeung
		 	Title:	 	Authorized Signatory
		
		 	 MHR CAPITAL PARTNERS (100) LP

By MHR Advisors LLC, its general partner

			
		 	By:	 	 /s/ Janet Yeung

		 	Name:	 	Janet Yeung
		 	Title:	 	Authorized Signatory
		
		 	 MHR INSTITUTIONAL PARTNERS II LP

By MHR Institutional Advisors II LLC, its general partner

			
		 	By:	 	 /s/ Janet Yeung

		 	Name:	 	Janet Yeung
		 	Title:	 	Authorized Signatory
		
		 	 MHR INSTITUTIONAL PARTNERS IIA LP

By MHR Institutional Advisors II LLC, its general partner

			
		 	By:	 	 /s/ Janet Yeung

		 	Name:	 	Janet Yeung
		 	Title:	 	Authorized Signatory

  
 -2- 

 Exhibit A 

Milestone Schedule 
 The
following shall each constitute a “Milestone” for purposes of the Note:  
 Net Product Sales Milestones: 

 

	 	1.	The Company shall have Net Product Sales during the fiscal year ended December 31, 2014 of at least $5.5 million.* 

  

	 	2.	The Company shall have Net Product Sales during the fiscal year ended December 31, 2015 of at least $17.5 million. 

  

	 	3.	The Company shall have Net Product Sales during the fiscal year ended December 2016 of at least $34.0 million. 

Operational Performance Milestones 
  

	 	1.	The Company shall have executed a license or distribution agreement for the sale of Eligen-B12 in at least one (1) Approved Jurisdiction on or prior to December 31, 2013.* 

 

	 	2.	The Company shall have executed one or more license or distribution agreements for the sale of Eligen-B12 in at least two (2) additional Approved Jurisdictions (for a total of at least three (3) Approved
Jurisdictions) on or prior to December 31, 2014.* 

  

	 	3.	The Company shall have executed one or more license or distribution agreements for the sale of Eligen-B12 in at least two (2) additional Approved Jurisdictions (for a total of at least five (5) Approved
Jurisdictions) on or prior to December 31, 2015.* 

  

	 	4.	The Company shall have executed a license or distribution agreement for the sale of Eligen-B12 in one (1) additional Approved Jurisdiction (for a total of at least six (6) Approved Jurisdictions) on or prior
to December 31, 2016.* 

 In the event that the Company does not satisfy one of the Operational Performance Milestones set
forth above, the Company shall have a grace period of four (4) months to satisfy such Operational Performance Milestone. The foregoing grace period shall only be available one time and shall not affect the total number of license or
distribution agreements that must be executed in subsequent periods. For example, in the event that the Company does not execute any license or distribution agreement for the sale of Eligen-B12 in an Approved Jurisdiction on or prior to
December 31, 2013, the Company must execute (a) one license or distribution agreement for the sale of Eligen-B12 in an Approved Jurisdiction by April 30, 2014 and (b) license and distribution agreements in at least three
(3) Approved Jurisdictions on or prior to December 31, 2014. 
 Eligen-B12 Manufacturing Milestone 

 

	 	1.	The Company shall have at least 4.5 million tablets of Eligen-B12 manufactured and available for commercial sale on or prior to April 26, 2014.* 

 

	*	Waiver Milestone 

  

 “Approved Jurisdiction” means any of the following countries or territories: Argentina,
Australia, Brazil, Canada, Chile, China, France, Hong Kong, Germany, India, Israel, Italy, Japan, Mexico, New Zealand, Peru, Singapore, Spain, South Korea, Switzerland, Turkey, United Kingdom or United States and such other countries with comparable
economic or strategic profiles as may be agreed by the Company and MHR in writing from time to time. 
 “Net Product Sales” means Revenues
for the applicable fiscal year resulting solely from the sale of the Company’s products that are not combined or proposed to be combined with proprietary technology or products of any other Person. The determination as to whether Net Product
Sales for any fiscal year shall have met or exceeded the applicable Milestone shall be made on the date that the Company’s independent registered public accounting firm delivers the audit report to the Board of Directors and stockholders of the
Company regarding the financial statements of the Company for such fiscal year. 
 “Revenues” means the amount ascribed to
“Revenues” in the Income Statement. 

 Exhibit B 

Revised Milestones 
 The following
revised Milestones shall replace the corresponding Waiver Milestone set forth in Exhibit A for purposes of the Note; all other Milestones remain unchanged: 

Net Product Sales Milestones: 
  

	 	1.	The Company shall have Net Product Sales during the period beginning March 31, 2014 and ending April 1, 2015 of at least $5.5 million. 

Operational Performance Milestones 
  

	 	1.	[Deleted.] 

  

	 	2.	The Company shall have executed one or more license or distribution agreements for the sale of Eligen-B12 in at least two (2) Approved Jurisdictions (for a total of at least two (2) Approved Jurisdictions) on
or prior to April 1, 2015. 

  

	 	3.	The Company shall have executed one or more license or distribution agreements for the sale of Eligen-B12 in at least two (2) additional Approved Jurisdictions (for a total of at least four (4) Approved
Jurisdictions) on or prior to December 31, 2015. 

  

	 	4.	The Company shall have executed a license or distribution agreement for the sale of Eligen-B12 in one (1) additional Approved Jurisdiction (for a total of at least five (5) Approved Jurisdictions) on or prior
to December 31, 2016. 

 In the event that the Company does not satisfy one of the Operational Performance Milestones set
forth above, the Company shall have a grace period of four (4) months to satisfy such Operational Performance Milestone. The foregoing grace period shall only be available one time and shall not affect the total number of license or
distribution agreements that must be executed in subsequent periods. For example, in the event that the Company does not execute license or distribution agreement for the sale of Eligen-B12 in at least two Approved Jurisdictions on or prior to
April 1, 2015, the Company must execute (a) license or distribution agreement for the sale of Eligen-B12 in two Approved Jurisdiction by August 1, 2015 and (b) license and distribution agreements in at least four
(4) Approved Jurisdictions on or prior to December 31, 2015. 
 Eligen-B12 Manufacturing Milestone 

 

	 	1.	The Company shall have at least 4.5 million tablets of Eligen-B12 manufactured and available for commercial sale on or prior to December 31, 2014.EX-10.45

 Exhibit 10.45 

EXECUTION VERSION 

FIRST AMENDMENT dated as of February 4, 2014 (this “Amendment Agreement”), to the Credit Agreement
dated as of April 25, 2013 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Credit Agreement”), among AFFINIA GROUP INTERMEDIATE HOLDINGS INC., a Delaware corporation
(“Holdings”), AFFINIA GROUP INC., a Delaware corporation (the “Borrower”), the LENDERS party thereto and JPMORGAN CHASE BANK, N.A. (“JPMCB”), as Administrative Agent. Capitalized terms used but not
defined herein have the meanings assigned to them in the Credit Agreement. J.P. Morgan Securities LLC has been appointed to act as sole lead arranger (in such capacity, the “Arranger”) in connection with this Amendment Agreement.

 W I T N E S S E T H: 

WHEREAS, pursuant to the Credit Agreement, the Lenders have made Term Loans to the Borrower on the terms and subject to the conditions set
forth therein; and 
 WHEREAS, Holdings, the Borrower and the Required Lenders desire to amend the Credit Agreement to (a) permit the
sale in one or more transactions of the Chassis Business (as defined below), (b) permit dividends and/or loans and advances to be used to repay the Dana Seller Note and (c) modify certain other terms and conditions of the Credit Agreement,
in each case on the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, the parties hereto agree as follows: 

SECTION 1. Amendment of Credit Agreement. Effective as of the First Amendment Effective Date (as defined below), the Credit Agreement
is hereby amended as follows: 
 (a) The following definitions are hereby added in the appropriate alphabetical order to
Section 1.01 of the Credit Agreement: 
 “Chassis Business” means the Borrower’s and its Subsidiaries’
steering, suspension and driveline component design, manufacturing, assembly, sale and distribution business. 
 (b) The
definition of the term “Dana Seller Note” set forth in Section 1.01 of the Credit Agreement is hereby amended by replacing the word “Holdings” with the word “Parent”. 

(c) Clause (a) of the definition of the term “Excess Cash Flow” set forth in Section 1.01 of the Credit
Agreement is hereby amended by (x) replacing the word “and” at the end of clause (i) thereof with a comma, (y) replacing the semicolon at the end of clause (ii) thereof with the word “and” and
(z) inserting a new clause (iii) immediately thereafter to read as follows: 

  

 “(iii) any gains or losses attributable to the sale of the Chassis Business;” 

(d) Clause (a)(i) of the definition of the term “Prepayment Event” set forth in Section 1.01 of the Credit
Agreement is hereby amended by (x) replacing the word “and” with a comma and (y) inserting after the reference to “(j)” therein the words “and (m)”. 

(e) Section 2.09(c) of the Credit Agreement is hereby amended by inserting the following sentence at the end thereof: 

“Notwithstanding the foregoing, any prepayment of Term Borrowings required to be made pursuant to this clause (c) in respect of the
four consecutive fiscal quarter period ending June 30, 2014, may be deferred until the date that is six months after the date such prepayment would be due were such deferral not permitted.” 

(f) Clause (x) of the proviso to Section 6.04(r) of the Credit Agreement is hereby amended by replacing the words
“18-month anniversary” with the words “24-month anniversary”. 
 (g) Section 6.04 of the Credit
Agreement is hereby amended by (x) deleting the word “and” at the end of clause (t) thereof, (y) replacing the period at the end of clause (u) thereof with a semicolon and inserting the word “and” immediately
thereafter and (z) inserting a new clause (v) to read as follows: 
 “(v) loans and advances to Holdings (and by Holdings to
its parent) in an aggregate amount not to exceed $85,000,000 less any amounts declared and paid as a Restricted Payment pursuant to Section 6.08(a)(xiii); provided that such loans or advances are used by Parent to repay outstanding
amounts under the Dana Seller Note.” 
 (h) Section 6.05 of the Credit Agreement is hereby amended by
(x) deleting the word “and” at the end of clause (k) thereof, (y) replacing the period at the end of clause (l) thereof with a semicolon and inserting the word “and” immediately thereafter and
(z) inserting a new clause (m) to read as follows: 
 “(m) the sale in one or more transactions of the Chassis Business;
provided that concurrently with such sale the Borrower prepays Term Borrowings in an aggregate amount of $75,000,000, which prepayment shall be allocated ratably between the Tranche B-1 Term Loans and the Tranche B-2 Term Loans.” 

(i) Clause (x) of the proviso to Section 6.08(a)(iii) of the Credit Agreement is hereby amended by replacing the
words “18-month anniversary” with the words “24-month anniversary”. 

  
 2 

 (j) Section 6.08(a) of the Credit Agreement is hereby amended by
(x) deleting the word “and” at the end of clause (xi) thereof, (y) replacing the period at the end of clause (xii) thereof with a semicolon and inserting the word “and” immediately thereafter and
(z) inserting a new clause (xiii) to read as follows: 
 “(xiii) the Borrower may declare and pay to Holdings, and Holdings
may declare and pay to its parent, dividends in an aggregate amount not to exceed $85,000,000 less any amounts used to make loans or advances pursuant to Section 6.04(v); provided such dividends are used by Parent to repay outstanding
amounts under the Dana Seller Note.” 
 SECTION 2. Waiver of Break Funding Payments. Each Lender that delivers a signature page
to this Amendment Agreement hereby waives and agrees that it shall not receive any break funding payments that would otherwise be payable under Section 2.14 of the Credit Agreement in connection with the prepayment of any Eurodollar Loans with
a portion of the cash proceeds of the sale of the Chassis Business. 
 SECTION 3. Conditions to Effectiveness of Amendment Agreement.
This Amendment Agreement shall become effective as of the first date on which the following conditions are satisfied or waived (the “First Amendment Effective Date”): 

(a) The Administrative Agent shall have received a counterpart of this Amendment Agreement, executed and delivered by a duly
authorized officer of Holdings, the Borrower, the Required Lenders and the Administrative Agent. 
 (b) The Borrower shall
have paid to the Administrative Agent, for the account of each Lender that timely delivers a signature page to this Amendment Agreement, an upfront fee equal to 0.15% of the aggregate principal amount of Term Loans held by such Lender on the First
Amendment Effective Date. 
 (c) The Borrower shall have paid to the Administrative Agent and the Arranger all other fees
and, to the extent invoiced at least two Business Days prior to the First Amendment Effective Date, reasonable and documented out-of-pocket expenses (including reasonable and documented fees, charges and disbursements of counsel) in each case due
and payable on or prior to the First Amendment Effective Date and required to be reimbursed or paid pursuant to the Loan Documents and any other agreement between the Borrower and the Arranger. 

(d) At the time of and immediately after giving effect to this Amendment Agreement, no Default shall have occurred and be
continuing or would result from this Amendment Agreement. 
 (e) The representations and warranties of each Loan Party made
or deemed to be made in this Amendment Agreement shall be true and correct in all material respects (or, in the case of representations and warranties qualified as to materiality, in all respects), except in the case of any such representation and
warranty that expressly relates to a prior date, in which case such representation and warranty shall be true and correct in all material respects (or in all respects, as applicable) as of such earlier date. 

  
 3 

 (f) The Administrative Agent shall have received a certificate, dated the First
Amendment Effective Date and signed by a Financial Officer or the President or a Vice President of the Borrower, confirming compliance with the conditions set forth in clauses (d) and (e) of this Section. 

SECTION 4. Representations and Warranties. Each of Holdings and the Borrower hereby represents and warrants to the Administrative Agent
and each Lender on the First Amendment Effective Date that: 
 (a) This Amendment Agreement has been duly authorized,
executed and delivered by each of Holdings and the Borrower and constitutes a legal, valid and binding obligation of each of Holdings and the Borrower, enforceable against Holdings and the Borrower in accordance with its terms, subject to applicable
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.

 (b) The representations and warranties of each Loan Party set forth in the Loan Documents are true and correct in all
material respects (or, in the case of representations and warranties qualified as to materiality, in all respects), except in the case of any such representation and warranty that expressly relates to a prior date, in which case such representation
and warranty was true and correct in all material respects (or in all respects, as applicable) as of such earlier date. 

(c) At the time of and immediately after giving effect to this Amendment Agreement, no Default has occurred and is continuing
or would result from this Amendment Agreement. 
 SECTION 5. Effects on Loan Documents; No Novation. (a) Except as expressly set
forth herein, this Amendment Agreement shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other provision of the Credit Agreement or of any
other Loan Document, all of which shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. 

(b) Except as expressly set forth herein, the execution, delivery and effectiveness of this Amendment Agreement shall not
operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents, nor constitute a waiver of any provision of the Loan Documents or in any way limit, impair or otherwise affect the rights
and remedies of the Administrative Agent or the Lenders under the Loan Documents. Nothing herein shall be deemed to entitle Holdings, the Borrower or any other Loan Party to a consent to, or a waiver, amendment, modification or other change of, any
of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances. 

  
 4 

 (c) On and after the First Amendment Effective Date, each reference in the
Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import, and each reference to the Credit Agreement “thereunder”, “thereof”, “therein” or
words of like import in any other Loan Document, shall be deemed a reference to the Credit Agreement as amended hereby. Holdings, the Borrower and the other parties hereto acknowledge and agree that this Amendment Agreement shall constitute a
“Loan Document”. 
 (d) This Amendment Agreement shall not extinguish the obligations for the payment of money
outstanding under the Credit Agreement or discharge or release the priority of any Security Document. Nothing herein contained shall be construed as a substitution or novation of the Obligations outstanding under the Credit Agreement or any other
Loan Document, all of which shall remain in full force and effect, except as modified hereby. Nothing expressed or implied in this Amendment Agreement or any other document contemplated hereby shall be construed as a release or other discharge of
any Loan Party under any Loan Document from any of its obligations and liabilities thereunder. 
 SECTION 6. GOVERNING LAW. THIS
AMENDMENT AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AMENDMENT AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 
 SECTION 7. Counterparts. This Amendment Agreement may be
executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a
signature page of this Amendment Agreement by facsimile transmission or other electronic imaging shall be effective as delivery of a manually executed counterpart of this Amendment Agreement. 

SECTION 8. Notices. All notices and other communications provided for herein shall be given in the manner, and become effective, as
set forth in Section 9.01 of the Credit Agreement. 
 [Remainder of page intentionally left blank.] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment Agreement to be duly executed
and delivered by their respective proper and duly authorized officers as of the day and year first above written. 
  

					
	AFFINIA GROUP INTERMEDIATE HOLDINGS INC.
			
		 	by	 	/s/ Steven P. Klueg
		 		 	Name: Steven P. Klueg
		 		 	 Title: Senior Vice President and

         Chief Financial Officer

	
	AFFINIA GROUP INC.
			
		 	by	 	/s/ Steven P. Klueg
		 		 	Name: Steven P. Klueg
		 		 	 Title: Senior Vice President and

         Chief Financial Officer

  

  
 [Signature Page to First
Amendment] 

 
			
	JPMORGAN CHASE BANK, N.A., individually as a Lender and as Administrative Agent
		
	        by	 	 /s/ Robert P. Kellas

		 	Name: Robert P. Kellas
		 	Title: Executive Director

  

  
 [Signature Page to First
Amendment] 

 SIGNATURE PAGE TO 

FIRST AMENDMENT 
 TO CREDIT AGREEMENT

  

					
	Name of
Lender:                                        

			
		 	By	 	  

		 		 	Name:
		 		 	Title:
	
	For any Lender requiring a second signature line:
	
	Name of
Lender:                                        

			
		 	By	 	  

		 		 	Name:
		 		 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]